Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 25;12(12):2678.
doi: 10.3390/biomedicines12122678.

Does Bisphenol A (BPA) Exposure Cause Human Diseases?

Affiliations
Review

Does Bisphenol A (BPA) Exposure Cause Human Diseases?

T Peter Stein. Biomedicines. .

Abstract

Background: Autism spectrum disorders (ASDs), attention-deficit disorder (ADHD), Parkinson's disease (PD), polycystic ovary disease (PCOS), and Alzheimer's disease (AD) have all been linked to exposure to bisphenol A (BPA).

Methods: This paper is a review and discussion of the published literature.

Results: Animal studies have shown BPA to be a broad-spectrum endocrine disruptor. BPA is metabolized via the glucuronidation pathway, which involves the addition of glucose to the target molecule, and is catalyzed by uridine 5'-diphospho-glucuronosyltransferases (UGTs). Evidence of compromised glucuronidation has been found for ASD, DHD, PD, and PCOS. Genetic polymorphisms that alter the catalytic activity of the UGTs and efflux transporters involved are common. There are two ways to interpret the findings of associations between BPA glucuronidation efficiency and disease, a 'direct' pathway and an 'indirect' pathway. With the 'direct' pathway, free BPA is the actual causative agent. Compromised BPA detoxification leads to higher concentrations of free BPA in vulnerable tissues. Decreased BPA detoxification leads to increased exposure of vulnerable tissues to free BPA, where it can function as an endocrine disruptor. With the 'indirect' pathway, BPA is not the causative agent. BPA serves as a marker for the decreased glucuronidation efficiency of another unknown compound of endogenous origin detoxified by a similar combination of UGTs and efflux transporters as BPA. It is this compound(s), acting as an endocrine disruptor, that leads to a metabolic environment that favors disease development over an extended time period.

Conclusion: A review of the existing literature supports the indirect 'marker' hypothesis over the 'direct' hypothesis.

Keywords: ADHD; Alzheimer’s; BPA; DEHP (diethyl hexyl phthalate); PCOS; Parkinson’s; autism; bisphenol A; glucuronidation.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Percentage of total number of Spearman’s rank-order correlations between glucuronidation efficiency, either +v or −ve, by glucuronidation pathway vs. individual metabolome compounds. Abbreviations: 5OX, 5-OXO MEHP; 5CX, 5-CX MEHP; 5OH, 5-OH MEHP; CRT, Cortisol; GDA, Glycocholate; GCA, Glycodeoxycholate; NAR, Naringenin; SAL, Salicylate.
Figure 2
Figure 2
Percent of total number of Spearman’s rank-order correlations from Figure 1, either positive or negative, by glucuronidation pathway for total metabolome. Abbreviations are the same as in Figure 1.

Similar articles

Cited by

References

    1. Mir R.H., Sawhney G., Pottoo F.H., Mohi-Ud-Din R., Madishetti S., Jachak S.M., Ahmed Z., Masoodi M.H. Role of environmental pollutants in Alzheimer’s disease: A review. Environ. Sci. Pollut. Res. 2021;27:44724–44742. doi: 10.1007/s11356-020-09964-x. - DOI - PubMed
    1. Lahiri D.K., Maloney B. The “LEARn” [latent early-life associated regulation] model: An epigenetic pathway linking metabolic and cognitive disorders. J. Alzheimer’s Dis. 2012;30:S15–S30. doi: 10.3233/JAD-2012-120373. - DOI - PubMed
    1. McCaffery P., Deutsch C.K. Macrocephaly and the control of brain growth in autistic disorders. Prog. Neurobiol. 2005;77:38–56. doi: 10.1016/j.pneurobio.2005.10.005. - DOI - PubMed
    1. Ishihara K., Takata K., Mizutani K.I. Involvement of an Aberrant Vascular System in Neurodevelopmental, Neuropsychiatric, and Neuro-Degenerative Diseases. Life. 2023;13:221. doi: 10.3390/life13010221. - DOI - PMC - PubMed
    1. Bleuze L., Triaca V., Borreca A. FMRP-Driven Neuropathology in Autistic Spectrum Disorder and Alzheimer’s disease: A Losing Game. Front. Mol. Biosci. 2021;8:699613. doi: 10.3389/fmolb.2021.699613. - DOI - PMC - PubMed

LinkOut - more resources